Discover how Evelo’s EDP1815 may prevent the progression of COVID-19. Learn More

skip to content

Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis

Cambridge, MA - December 3, 2020

Read the original article here